- Home
- BIRD vs KYNB Comparison
BIRD vs KYNB Comparison
Compare BIRD & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | KYNB |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 32.8M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BIRD | KYNB |
|---|---|---|
| Price | $2.86 | $6.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | ★ 496.5K | 24.8K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.22 | ★ 9552.08 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,466,000.00 | $6,440,000.00 |
| Revenue This Year | N/A | $4.23 |
| Revenue Next Year | $487.91 | $14.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $5.62 |
| 52 Week High | $24.31 | $9.66 |
Technical Indicators
Market Signals| Indicator | BIRD | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 31.79 |
| Support Level | $2.26 | $5.62 |
| Resistance Level | $3.25 | $7.41 |
| Average True Range (ATR) | 0.25 | 0.33 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 36.27 | 23.81 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Smartbird Inc delivers dedicated AI infrastructure as a service, giving organizations the performance, control, and security of a private AI cluster without requiring them to finance, operate, or maintain the underlying infrastructure. Smartbird manages the entire lifecycle, from procurement and deployment to operations and hardware refreshes, so customers can focus on AI workloads, not AI infrastructure.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.